Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigation of the Therapeutic Potential of Fibroblast Activation Protein Inhibition in Type 2 Diabetes

Award Number: F32DK107050
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/22/2016
PERIOD OF PERFORMANCE END DATE: 09/21/2019

Group Awards By:

View Award Description

Investigation of the Therapeutic Potential of Fibroblast Activation Protein Inhibition in Type 2 Diabetes - Project Summary Globally, the number of people with type 2 diabetes mellitus (T2D) is approaching 350 million [1]. With this number rapidly rising, the urgent need for effective therapeutics to treat this disease is also increasing. Research efforts have produced significant advances in treatment options, including the introduction of dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and SGLT2 inhibitors to improve glucose-stimulated insulin secretion and lower blood glucose. Despite these advances, there remains a gap in the normalization of glucose and the prevention of complications among the population that current treatments have been unable to address, leaving millions of patients with insufficient and unsafe levels of glucose control. Recently, a protease enzyme called fibroblast activation protein (FAP) has emerged as a potential target for the treatment of T2D and obesity [2]. FAP is the most closely related enzyme to DPP4 [3, 4], a validated drug target. Multiple pharmacological inhibitors of DPP4 are now widely used in patients with T2D [5]. Previous interest in FAP has focused on its potential as a target for cancer therapy due to its upregulation in epithelial tumors [6]. However, recent FAP-specific activity assays have identified FAP activity in the circulation, as well as in several tissues with roles in metabolic regulation [7]. Most intriguingly, preliminary characterization of a global FAP knockout (Fap-/-) mouse demonstrated a) significant protection against diet-induced obesity and b) improved glycemia, phenotypic findings similar to those described in the global DPP4 knockout (Dpp4-/-) mouse [2]. Importantly, FAP has a unique endopeptidase activity, suggesting that its enzymatic targets are different from those of DPP4. Thus, FAP inhibition may provide a novel route to treatment of diabetes. We have independently generated mutant Fap-/- mice, enabling us to determine the metabolic phenotype ensuing from genetic FAP deficiency. Complementary experiments will utilize a potent and specific FAP inhibitor, compound 5057, to determine whether pharmacological FAP inhibition produces the same metabolic benefits observed in Fap-/- mice. Fap-/- mice and wild-type mice treated with compound 5057 will be employed to identify physiological mechanisms (and FAP substrates) underlying the metabolic benefits of FAP inactivation. We are hopeful that this research will lay the groundwork for clinical testing of a new class of drugs for the treatment of T2D.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = -$1,727 )
2021	2018	SINAI HEALTH SYSTEM	600 UNIVERSITY AVE	TORONTO	ON			CAN	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	12/28/2020	NON-COMPETING CONTINUATION	-$1,727
														Subtotal = -$1,727

Issue Date FY: 2018 ( Subtotal = $9,850 )
2018	2018	SINAI HEALTH SYSTEM	600 UNIVERSITY AVE	TORONTO	ON	M5G 1X5		CAN	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	8/24/2018	NON-COMPETING CONTINUATION	$9,850
														Subtotal = $9,850

Issue Date FY: 2017 ( Subtotal = $8,850 )
2017	2017	SINAI HEALTH SYSTEM	600 UNIVERSITY AVE	TORONTO	ON	M5G 1X5		CAN	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	9/6/2017	NON-COMPETING CONTINUATION	$8,850
														Subtotal = $8,850

Issue Date FY: 2016 ( Subtotal = $8,850 )
2016	2016	MOUNT SINAI HOSPITAL	600 UNIVERSITY AVENUE	TORONTO				CAN	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	1	9/21/2016	NEW	$0
2016	2016	MOUNT SINAI HOSPITAL	600 UNIVERSITY AVENUE	TORONTO				CAN	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	1	9/21/2016	NEW	$8,850
														Subtotal = $8,850

Grand Total All Awards = $25,823

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigation of the Therapeutic Potential of Fibroblast Activation Protein Inhibition in Type 2 Diabetes

Award Number: F32DK107050

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/22/2016

PERIOD OF PERFORMANCE END DATE: 09/21/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer